Alcon launched Tryptyr, a treatment for the signs and symptoms of dry eye disease, in the U.S.
Tryptyr (acoltremon ophthalmic solution 0.003%) is a TRPM8 receptor agonist that showed a “statistically significant increase in natural tear production as early as day 1” in the phase 3 COMET-2 and COMET-3 studies, according to a press release.
In addition, Alcon launched a campaign focused on the efficacy of the drop in increasing the speed of natural tear production, including videos and interactive websites for eye care professionals and patients. The Tryptyr launch (Read more...)